

References

Panés J, Rubin DT, Vermeire S, et al. Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis. [Su1932] Poster presented at: Digestive Disease Week 2017; May 7, 2017; Chicago, IL.

D'Haens G, Schreiber S, Petryka R, et al. Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY Study in moderate-to-severe Crohn's disease. [Su1920] Poster presented at: Digestive Disease Week 2017; May 7, 2017; Chicago, IL.

Vermeire S, Schreiber S, Petryka R, et al. Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study. [Su1930] Poster presented at: Digestive Disease Week 2017; May 7, 2017; Chicago, IL.

